Cargando…

Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus

H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Isakova-Sivak, Irina, de Jonge, Jørgen, Smolonogina, Tatiana, Rekstin, Andrey, van Amerongen, Geert, van Dijken, Harry, Mouthaan, Justin, Roholl, Paul, Kuznetsova, Victoria, Doroshenko, Elena, Tsvetnitsky, Vadim, Rudenko, Larisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109939/
https://www.ncbi.nlm.nih.gov/pubmed/25058039
http://dx.doi.org/10.1371/journal.pone.0102339
_version_ 1782327935740411904
author Isakova-Sivak, Irina
de Jonge, Jørgen
Smolonogina, Tatiana
Rekstin, Andrey
van Amerongen, Geert
van Dijken, Harry
Mouthaan, Justin
Roholl, Paul
Kuznetsova, Victoria
Doroshenko, Elena
Tsvetnitsky, Vadim
Rudenko, Larisa
author_facet Isakova-Sivak, Irina
de Jonge, Jørgen
Smolonogina, Tatiana
Rekstin, Andrey
van Amerongen, Geert
van Dijken, Harry
Mouthaan, Justin
Roholl, Paul
Kuznetsova, Victoria
Doroshenko, Elena
Tsvetnitsky, Vadim
Rudenko, Larisa
author_sort Isakova-Sivak, Irina
collection PubMed
description H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study.
format Online
Article
Text
id pubmed-4109939
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41099392014-07-29 Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus Isakova-Sivak, Irina de Jonge, Jørgen Smolonogina, Tatiana Rekstin, Andrey van Amerongen, Geert van Dijken, Harry Mouthaan, Justin Roholl, Paul Kuznetsova, Victoria Doroshenko, Elena Tsvetnitsky, Vadim Rudenko, Larisa PLoS One Research Article H2N2 Influenza A caused the Asian flu pandemic in 1957, circulated for more than 10 years and disappeared from the human population after 1968. Given that people born after 1968 are naïve to H2N2, that the virus still circulates in wild birds and that this influenza subtype has a proven pandemic track record, H2N2 is regarded as a potential pandemic threat. To prepare for an H2N2 pandemic, here we developed and tested in mice and ferrets two live attenuated influenza vaccines based on the haemagglutinins of the two different H2N2 lineages that circulated at the end of the cycle, using the well characterized A/Leningrad/134/17/57 (H2N2) master donor virus as the backbone. The vaccine strains containing the HA and NA of A/California/1/66 (clade 1) or A/Tokyo/3/67 (clade 2) showed a temperature sensitive and cold adapted phenotype and a reduced reproduction that was limited to the respiratory tract of mice, suggesting that the vaccines may be safe for use in humans. Both vaccine strains induced haemagglutination inhibition titers in mice. Vaccination abolished virus replication in the nose and lung and protected mice from weight loss after homologous and heterologous challenge with the respective donor wild type strains. In ferrets, the live attenuated vaccines induced high virus neutralizing, haemagglutination and neuraminidase inhibition titers, however; the vaccine based on the A/California/1/66 wt virus induced higher homologous and better cross-reactive antibody responses than the A/Tokyo/3/67 based vaccine. In line with this observation, was the higher virus reduction observed in the throat and nose of ferrets vaccinated with this vaccine after challenge with either of the wild type donor viruses. Moreover, both vaccines clearly reduced the infection-induced rhinitis observed in placebo-vaccinated ferrets. The results favor the vaccine based on the A/California/1/66 isolate, which will be evaluated in a clinical study. Public Library of Science 2014-07-24 /pmc/articles/PMC4109939/ /pubmed/25058039 http://dx.doi.org/10.1371/journal.pone.0102339 Text en © 2014 Isakova-Sivak et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Isakova-Sivak, Irina
de Jonge, Jørgen
Smolonogina, Tatiana
Rekstin, Andrey
van Amerongen, Geert
van Dijken, Harry
Mouthaan, Justin
Roholl, Paul
Kuznetsova, Victoria
Doroshenko, Elena
Tsvetnitsky, Vadim
Rudenko, Larisa
Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title_full Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title_fullStr Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title_full_unstemmed Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title_short Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
title_sort development and pre-clinical evaluation of two laiv strains against potentially pandemic h2n2 influenza virus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109939/
https://www.ncbi.nlm.nih.gov/pubmed/25058039
http://dx.doi.org/10.1371/journal.pone.0102339
work_keys_str_mv AT isakovasivakirina developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT dejongejørgen developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT smolonoginatatiana developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT rekstinandrey developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT vanamerongengeert developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT vandijkenharry developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT mouthaanjustin developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT rohollpaul developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT kuznetsovavictoria developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT doroshenkoelena developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT tsvetnitskyvadim developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus
AT rudenkolarisa developmentandpreclinicalevaluationoftwolaivstrainsagainstpotentiallypandemich2n2influenzavirus